Does pemigatinib target FGFR3?

Pemigatinib (Pemigatinib) is a drug targeting the FGFR (fibroblast growth factor receptor) family. Specifically, pemetinib mainly inhibits three receptors: FGFR1, FGFR2 and FGFR3. In some patients with cholangiocarcinoma, FGFR gene mutations can lead to abnormal activity of the FGFR signaling pathway and promote the proliferation and survival of tumor cells. Pemetinib, as a targeted therapy drug, interferes with this abnormal signaling pathway by selectively inhibiting the activity of FGFR receptors, thereby blocking the growth and spread of tumor cells. Although pemetinib mainly inhibits FGFR1, FGFR2 and FGFR3, its inhibitory effect on other FGFR subtypes is weak. This targeting specificity helps reduce adverse effects on normal cells and improves the drug's safety.